| Lung Non-Small Cell Carcinoma studied in …STUDIED_INderived200 of 6,742show all (up to 200) |
|---|
| → studied in | NCT00068003enrolling by invitation Harvesting Cells for Experimental Cancer Treatments · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02146170recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04405401Phase 2 · terminated Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04487080Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04988295Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05388669Phase 3 · active not recruiting A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498428Phase 2 · recruiting A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05642195Phase 1/Phase 2 · suspended Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05753722Phase 1 · completed A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06931717Phase 3 · recruiting A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005297not yet recruiting Clinical Genetics Branch Eligibility Screening Survey · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Pulmonary Blastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07144280Phase 3 · recruiting A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07190248Phase 3 · recruiting A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513376Phase 3 · recruiting A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02609776Phase 1 · active not recruiting Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568656Phase 1/Phase 2 · completed Study to Evaluate CCS1477 in Advanced Tumours · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253964Phase 2 · recruiting Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132075Phase 3 · active not recruiting Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269485Phase 2 · completed Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05430802Phase 2 · active not recruiting Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05488314Phase 1/Phase 2 · active not recruiting A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647122Phase 1 · active not recruiting First in Human Study of AZD9592 in Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663866Phase 2 · active not recruiting Premedication to Reduce Amivantamab Associated Infusion Related Reactions · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908734Phase 1/Phase 2 · active not recruiting A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920356Phase 3 · recruiting A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06068049recruiting OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06116786Phase 1 · active not recruiting A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120140Phase 2 · active not recruiting Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170788Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06172478Phase 2 · recruiting A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218914Phase 1 · recruiting Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312137Phase 3 · recruiting A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06498635Phase 3 · recruiting Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06579196Phase 1/Phase 2 · active not recruiting Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667076Phase 2 · recruiting A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667908Phase 2 · recruiting A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06758401Phase 3 · recruiting This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868277Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06919874NA · recruiting Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06924606Phase 2 · terminated Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07154290Phase 2 · recruiting A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07155187Phase 2/Phase 3 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07183189Phase 3 · active not recruiting A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222566Phase 3 · recruiting Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227025Phase 1/Phase 2 · recruiting A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227298Phase 1/Phase 2 · recruiting Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07230691recruiting A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07360743Phase 2 · recruiting Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489066Phase 2 · recruiting Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07579221Phase 1/Phase 2 · recruiting Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07586202Phase 2 · recruiting A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647094Phase 2 · recruiting A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07659782Phase 2 · recruiting A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663630Phase 1 · not yet recruiting A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670312Phase 1/Phase 2 · recruiting Evaluation of XYA02 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842471Phase 2 · not yet recruiting Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03191149Phase 2 · recruiting Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04844073Phase 1/Phase 2 · terminated A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215340Phase 3 · active not recruiting Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05363319recruiting An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05717998active not recruiting Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06096844Phase 3 · recruiting Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06447662Phase 1 · active not recruiting A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06605404recruiting Pan-tumor MRD Study · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890598Phase 3 · recruiting Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565987NA · not yet recruiting The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833202Phase 3 · not yet recruiting A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838532completed Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03340506Phase 4 · recruiting Dabrafenib and/or Trametinib Rollover Study · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03381274Phase 1/Phase 2 · active not recruiting Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04044859Phase 1 · active not recruiting ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04062708Phase 2 · active not recruiting CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05061550Phase 2 · recruiting Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05144997Phase 4 · active not recruiting Lorlatinib Continuation Study · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05312840Phase 2 · completed Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05607108Phase 2 · recruiting A Study of ZEN003694 in People With Squamous Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715229Phase 2 · terminated Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253520Phase 1 · active not recruiting Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337552NA · active not recruiting High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357533Phase 3 · recruiting Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06452277Phase 3 · recruiting A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06491862recruiting RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561386Phase 3 · recruiting A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564844Phase 3 · active not recruiting A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627647Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07140016Phase 1 · recruiting A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339176Phase 1/Phase 2 · recruiting Intratumoral N17350 in Advanced Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07661966NA · recruiting Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822880Phase 4 · not yet recruiting A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836543Phase 2 · not yet recruiting Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07837739recruiting Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04928846Phase 3 · recruiting A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009836Phase 3 · active not recruiting Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215548Phase 2 · recruiting Primary Tumor Resection With EGFR TKI for Stage IV NSCLC · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05696782Phase 2 · recruiting Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05745740Phase 1/Phase 2 · not yet recruiting A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06066138Phase 1 · recruiting A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06128551Phase 1/Phase 2 · recruiting Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140836Phase 3 · active not recruiting A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151574Phase 3 · active not recruiting Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06568939Phase 2 · recruiting A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712316Phase 2/Phase 3 · recruiting Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06714617Phase 1 · terminated Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06772623Phase 1/Phase 2 · recruiting Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06875310Phase 3 · recruiting A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07028489recruiting Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07100080Phase 2/Phase 3 · recruiting Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07104630Phase 2 · recruiting Pulmonary Rehabilitation in Advanced Lung Cancer Survivors · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07174388recruiting An External Control Arm Study in Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07186699recruiting Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801508Phase 1 · recruiting A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07816380Phase 3 · not yet recruiting A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01350817Phase 2 · completed Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793179Phase 3 · active not recruiting Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04032418Phase 2 · active not recruiting Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644068Phase 1/Phase 2 · active not recruiting Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983432Phase 1 · recruiting Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06114511Phase 1/Phase 2 · active not recruiting A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06529822Phase 1 · recruiting Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06732401Phase 3 · active not recruiting Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745882Phase 2 · recruiting Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834074available Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07431827Phase 3 · recruiting MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554339Phase 3 · recruiting A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07629960Phase 1/Phase 2 · recruiting A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07823725NA · not yet recruiting TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830342Phase 1 · not yet recruiting A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831863Phase 3 · not yet recruiting A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01720186NA · terminated Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410043Phase 2 · active not recruiting Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04291755enrolling by invitation Development and Analysis of a Stool Bank for Cancer Patients · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04638751suspended ARGONAUT: Stool and Blood Sample Bank for Cancer Patients · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05017025Phase 1/Phase 2 · completed Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267626Phase 1/Phase 2 · recruiting Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05863052active not recruiting Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06077760Phase 3 · active not recruiting A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06616623Phase 1 · suspended Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692738Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06767514Phase 3 · recruiting Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855771Phase 2 · recruiting A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07147361active not recruiting Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07388524Phase 3 · recruiting Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07435038Phase 1/Phase 2 · recruiting Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07617337Phase 1 · recruiting AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705334Phase 1 · recruiting A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827261Phase 2 · not yet recruiting A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827885NA · completed 20-Fr Versus 24-Fr Chest Drains After Uniportal VATS Lobectomy for NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393625Phase 1 · active not recruiting Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04105270Phase 2 · recruiting RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04152499Phase 1/Phase 2 · active not recruiting Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544748Phase 1 · completed A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04738487Phase 3 · terminated Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05937074terminated Metabolic Response to Food in Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07020117Phase 1 · recruiting A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07084610Phase 2 · recruiting Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07109726Phase 1/Phase 2 · recruiting A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · condition mapped ONTOLOGY_EXACT · 6,742 trials mapped (2,072 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172802Phase 1/Phase 2 · recruiting A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195695Phase 3 · recruiting Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07349537Phase 1 · recruiting Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365319Phase 2/Phase 3 · recruiting A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07566052Phase 3 · recruiting A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07567352active not recruiting A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578571Phase 1 · recruiting A Phase 1 Study of IM-1617 in Participants With Advanced Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824882Phase 2 · not yet recruiting A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01629498Phase 1/Phase 2 · active not recruiting Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03831932Phase 1/Phase 2 · active not recruiting Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04077099Phase 1/Phase 2 · active not recruiting A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486833Phase 1/Phase 2 · recruiting Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04613596Phase 2/Phase 3 · recruiting Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010109NA · recruiting Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208944Phase 2 · active not recruiting THIO Sequenced With Cemiplimab in Advanced NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05457049recruiting Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05681780Phase 1 · recruiting Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05786924Phase 1/Phase 2 · recruiting Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06008730Phase 2 · recruiting Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06497556Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259447NA · active not recruiting Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07323732Phase 2 · recruiting A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619339Phase 1 · recruiting A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07680764Phase 2 · recruiting A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · condition mapped CURATED_BROADER · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07806773Phase 2 · not yet recruiting Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07821684Phase 3 · not yet recruiting A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822542Phase 3 · not yet recruiting A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · condition mapped ALIAS · 6,742 trials mapped (2,072 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |